Thomas Smith
Stock Analyst at Leerink Partners
(1.06)
# 3,649
Out of 4,876 analysts
67
Total ratings
29.51%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $0.32 | +213.48% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $1.51 | +496.03% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $1.46 | +381.10% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $3.02 | +860.26% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $10.68 | +265.17% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $7.87 | +230.37% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $80 | $8.28 | +866.18% | 2 | Feb 21, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $7.43 | +169.18% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $560.14 | -22.34% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $54.51 | -33.95% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $1.00 | +600.00% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $16.10 | +30.48% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $14.33 | +214.03% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $5.62 | +6.76% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $3.76 | +59.57% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.69 | +620.46% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $47.58 | -64.27% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $20.28 | +215.58% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $17.08 | +309.84% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $9.86 | +194.12% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $2.69 | +866.54% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $26.52 | -54.75% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.69 | +171.00% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $3.42 | +11,595.91% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $13.49 | +493.03% | 2 | Dec 8, 2020 |
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.32
Upside: +213.48%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $1.51
Upside: +496.03%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $1.46
Upside: +381.10%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $3.02
Upside: +860.26%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $10.68
Upside: +265.17%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $7.87
Upside: +230.37%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $80
Current: $8.28
Upside: +866.18%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $7.43
Upside: +169.18%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $560.14
Upside: -22.34%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $54.51
Upside: -33.95%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $1.00
Upside: +600.00%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $16.10
Upside: +30.48%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $14.33
Upside: +214.03%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $5.62
Upside: +6.76%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $3.76
Upside: +59.57%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.69
Upside: +620.46%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $47.58
Upside: -64.27%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $20.28
Upside: +215.58%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $17.08
Upside: +309.84%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $9.86
Upside: +194.12%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.69
Upside: +866.54%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $26.52
Upside: -54.75%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.69
Upside: +171.00%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $3.42
Upside: +11,595.91%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $13.49
Upside: +493.03%